Hemophilia Treatment Drugs Market Revenue is expected to Surpass US$25.1 bn in 2024
According to the research report, the global hemophilia treatment drugs market is expected to be worth US$25.1 bn in 2024 as compared to US$15.8 bn in 2015. During the forecast period of 2016 and 2024, the overall market is expected to progress at a CAGR of 5.4%.
North America Moves Forward with Well-established Healthcare Infrastructure
The various products available in the global hemophilia treatment drugs market are recombinant coagulation factor concentrates, plasma derived coagulation factor concentrates, desmopressin, and antifibrinolytic agents. Of these, the recombinant coagulation factor concentrates are poised to lead the global market as the segment estimated to acquire a share of 46.9% by the end of 2024. The growing preference for recombinant factor therapies due to the low risk of blood-related infections is expected to fuel the growth of this segment.
Read Report overview @ https://www.transparencymarketresearch.com/hemophilia-treatment-market.html
Geographically, this market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, North America is likely to dominate the global market in the coming years due to the well-established healthcare infrastructure and the rising disposable incomes. The growing awareness amongst citizens about the various treatments available to treat diseases is also likely to boost the growth of the overall market. The report suggests that the North America hemophilia treatment drugs market is expected to lead the global market with a share of 40.6% by the end of 2024.
Investments in Developing Breakthrough Products to Augment Demand for Drugs
“The global hemophilia treatment drugs market is on the cusp of a major revolution as a large number of new drugs are expected to create a wave of change,” states the lead author of this research report. These drugs come with a promise of long-lasting clotting factors. For instance, “emicizumab” being developed by Roche has shown possibility of prophylactic efficiency in people who suffer from severe Hemophilia A. The growing focus on prophylaxis treatment to manage bleeding episodes by regularly infusing clotting factor concentrates is expected to propel the overall market. Demand for this type of treatment is expected to spike as the regular infusion of clotting factors can transform severe hemophilia to moderate hemophilia over time.
The market is also thriving due to the increasing investments in developing breakthrough products. For instance, in July 2016, Pfizer and Spark Therapeutics received FDA approval for “SPK-9001”, a drug that is being tested for being a one-time therapy for treating Hemophilia B. Furthermore, incentives by the FDA for orphan drugs such as tax credits, market exclusivity, and grants are expected to propel the market in the positive direction in the coming years as well.
Low Rate of Diagnosis Restrains Sale of Drugs
The biggest challenge in the global hemophilia treatment drugs market is the low rate of diagnosis amongst patients. Though genetic testing is available for this disease, several patients remain unaware of it due to lack of awareness, especially in the remote regions of the world. The market is also being restrained due to the high cost of drugs and even costlier rate of therapy to treat the disease.
This review is based on Transparency Market Research’s report, titled “Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 – 2024.”
Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1900
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
TMR Blog: http://www.theglobalhealthnews.com/
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia Treatment Drugs Market Revenue is expected to Surpass US$25.1 bn in 2024 here
News-ID: 851984 • Views: 155
More Releases from Transparency Market Research
Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15
More Releases for Drugs
Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market – Industry Analysis and Forecast (2018-2026) – by Drug Class, Indications, Distribution Channels, and Region. Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2017 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6 % during the forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data,
Cardiovascular Drugs Market | Insights
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven
Immunotherapy Drugs Market
Immunotherapy drugs are used to treat cancer, infection, respiratory and autoimmune disorders. Immunotherapies either stimulate the activities done by specific components of the immune system or counteract the signals that are produced by the cancer cells and suppress the immune responses. The Immunotherapy Drugs Market accounted to USD 107 billion in 2016 growing at a CAGR of 13.2% during the forecast period of 2017 to 2024. The upcoming market report contains
Immunotherapy Drugs Market
Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers. Immune effector cells includingmacrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to
Erythropoietin Drugs Market
Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA technology has allowed researchers to develop synthetic forms of